4DX

A bipartisan US House bill directing the VA to adopt 4D lung imaging for veteran respiratory disease screening represents sustained congressional support and a potential $20m pilot contract opportunity for 4DMedical's FDA-cleared XV LVAS product. The announcement highlights established US commercial infrastructure and validated clinical efficacy in detecting service-related lung conditions missed by standard tests.

4DMedical has halted trading pending disclosure of regulatory/legislative risk tied to a proposed US Congress bill affecting its lung-imaging business. The halt suggests material but currently unquantified implications requiring urgent market notification.

4DX has requested a pause in trading with no visible announcement body, suggesting a material corporate action may be pending (capital raise, M&A, or clinical milestone). Retail buying pressure ($2.9m in 5d) contrasts sharply with the -5% price move, indicating potential divergence between retail interest and institutional positioning ahead of news.

State Street Global Advisors ceased its substantial holding in 4DX via collateral reductions across 27–28 May, likely a routine passive rebalancing by a major index fund manager rather than a vote of no confidence. The 8% run-up over 20 days and modest 2% gain in the past 5 days suggest limited negative pricing impact.